Treatments for Anaplastic Thyroid Cancer

 Treatments for Anaplastic Thyroid Cancer

Drugs used to treat Anaplastic Thyroid Cancer

 

selpercatinib

Hicon

dabrafenib

Cabometyx

Westhroid

vandetanib

thyrotropin alpha

trametinib

Mekinist

Tafinlar

cabozantinib

Retevmo

NP Thyroid

doxorubicin

thyroid desiccated

sodium iodide-i-131

sorafenib

Cometriq

Nature-Throid

lenvatinib

Lenvima

Thyrogen

Caprelsa

Nexavar

Armour Thyroid

pralsetinib

Niva Thyroid

i3odine Max

Gavreto

APur Thyroid

WP Thyroid

 

What is Anaplastic Thyroid Cancer?

 

Anaplastic Thyroid Cancer (ATC) is one of the most aggressive and rare forms of thyroid cancer. It accounts for **less than 2%** of all thyroid cancers but is responsible for a significant portion of thyroid cancer-related deaths due to its rapid progression and poor prognosis. Below is a comprehensive overview:

 

1. Characteristics of ATC

- Aggressive Nature: ATC grows and spreads rapidly, often invading nearby tissues and metastasizing to distant organs, such as the lungs, bones, and brain, even at the time of diagnosis.

- Histology: Under the microscope, ATC cells appear poorly differentiated or undifferentiated, which is indicative of their inability to perform normal thyroid cell functions.

- Symptoms:

  - Rapidly growing neck mass.

  - Difficulty swallowing dysphagia).

  - Difficulty breathing (dyspnea), sometimes necessitating a tracheostomy.

  - Hoarseness due to vocal cord paralysis caused by tumor invasion.

  - Neck pain or tenderness.

- Age Group: Most cases occur in older adults, typically aged 60–80 years, and it is slightly more common in women.

 

2. Causes and Risk Factors

While the exact causes of ATC are unclear, some contributing factors include:

- Pre-existing thyroid conditions:

  - A history of other thyroid cancers (e.g., papillary or follicular thyroid cancer).

  - Long-standing goiter.

- Genetic Mutations: ATC is often associated with genetic changes, including mutations in:

  - TP53: A tumor suppressor gene commonly mutated in aggressive cancers.

  - BRAF: Frequently seen in both ATC and papillary thyroid carcinoma.

  - RAS mutations and TERT promoter mutations: Contributing to cellular immortality.

- Radiation Exposure: A history of radiation to the head or neck.

- Chronic Inflammation: Thyroiditis may predispose individuals to malignant transformation.

 

3. Diagnosis

- Clinical Examination: Rapidly enlarging neck mass, often hard and fixed, is a common presenting symptom.

- Imaging:

  - Ultrasound: Identifies the extent of thyroid involvement and guides biopsy.

  - CT/MRI: Helps assess local invasion into adjacent structures like the trachea or esophagus.

  - PET/CT: Detects distant metastases.

- Biopsy:

  - Fine Needle Aspiration (FNA): Common initial step but may require confirmation with a core biopsy due to insufficient sampling.

  - Histopathology confirms the undifferentiated nature of the tumor.

- Molecular Testing: Identifies actionable mutations (e.g., BRAF, NTRK).

 

4. Staging

ATC is classified as Stage IV regardless of tumor size or spread due to its aggressive nature:

- IVA: Tumor confined to the thyroid gland.

- IVB: Tumor invades adjacent structures (e.g., trachea, esophagus).

- IVC: Distant metastases are present.

 

5. Treatment

ATC is notoriously difficult to treat due to its rapid growth and resistance to conventional therapies. A multimodal approach is often employed:

 

a. Surgery

- Feasibility: Complete surgical resection is rare because the tumor often invades critical structures.

- Goal: When possible, surgery aims to reduce tumor burden or palliate symptoms.

 

b. Radiation Therapy

- External Beam Radiation Therapy (EBRT): Delivered to control local disease, often combined with chemotherapy.

- Hyperfractionated Schedules: May improve local control in selected patients.

 

c. Chemotherapy

- Cytotoxic Agents: Doxorubicin and cisplatin are traditionally used but have limited effectiveness.

- Targeted Therapy:

  - BRAF inhibitors (e.g., dabrafenib) and MEK inhibitors (e.g., trametinib): Effective in patients with BRAF-mutated tumors.

  - NTRK inhibitors: Used for tumors with NTRK gene fusions.

 

d. Immunotherapy

- Checkpoint Inhibitors: Emerging role in ATC with specific molecular profiles, but clinical evidence is limited.

 

e. Palliative Care

- Essential for patients with unresectable disease or extensive metastasis. Focuses on symptom relief, such as airway management.

 

6. Prognosis

- Survival Rates:

  - The 1-year survival rate is about 20–40%.

  - Median survival is typically 6 months after diagnosis.

- Factors Influencing Prognosis:

  - Tumor resectability.

  - Absence of distant metastasis.

  - Presence of actionable mutations responsive to targeted therapy.

- Challenges:

  - Late-stage diagnosis.

  - High rates of recurrence and metastasis.

 

7. Research and Advances

- Precision Medicine: Molecular profiling has improved personalized treatment approaches.

- Combination Therapies: Trials combining targeted therapy with radiation or immunotherapy show promise.

- Novel Agents: Drugs targeting specific pathways like PI3K, VEGF, or immune checkpoints are under investigation.

 

8. Prevention and Monitoring

- Early Detection: Regular monitoring of thyroid nodules or pre-existing thyroid conditions is key.

- Lifestyle Changes: While there are no definitive preventive measures, reducing exposure to radiation and managing thyroid health may lower risk.

 

Summary

Anaplastic Thyroid Cancer is a rare but highly aggressive cancer with limited treatment options and a poor prognosis. Advances in molecular medicine and targeted therapies offer hope for improved outcomes. Early diagnosis and a multidisciplinary treatment approach are critical for managing this challenging disease.